Pharmacist Digest

Lynozyfic receives EU approval for relapsed multiple myeloma treatment

Pharma Times

APRIL 30, 2025

New therapy offers hope for patients with limited option

Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine

Pharma Times

APRIL 22, 2025

The SHIELD-Utah study compared Novavaxs vaccine to Pfizer/BioNTech mRNA 2024 to 2025 vaccine

Vaccines

FDA approves Click’s digital therapeutic for episodic migraine

Pharma Times

APRIL 17, 2025

More than 37 million adults in the US are affected by migraine

Lab-grown lung cancer cells show potential to revolutionise treatment

Pharma Times

APRIL 10, 2025

The model could lead to more targeted treatments for the disease

First treatment for common bladder cancer recommended by NICE

Pharma Times

APRIL 10, 2025

Johnson & Johnsons Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration

SkyCell and Microsoft partner to improve pharma supply chains

Pharma Times

APRIL 9, 2025

AI-powered SkyMind is designed to improve efficiency, compliance and decision-making

MHRA approves prostate cancer imaging agent trofolastat

Pharma Times

APRIL 8, 2025

Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK

SMC approves bimekizumab for hidradenitis suppurativa treatment

Pharma Times

APRIL 7, 2025

The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional systemic therapies. This approval makes Scotland the first country in the UK to offer bimekizumab for HS patients. HS is a chronic inflammatory skin condition affecting 0.77% of the UK population.

Endlyz Therapeutics emerges with pipeline for Parkinson’s disease

Pharma Times

APRIL 7, 2025

Research targets lysosomal function restoration for neurodegeneration

Elekta and Azra AI partner to advance cancer registry operations with AI

Pharma Times

APRIL 3, 2025

Collaboration introduces automation to enhance efficiency

4basebio receives MHRA licence for synthetic DNA manufacture

Pharma Times

APRIL 2, 2025

GMP certification enables 4basebio to supply DNA for clinical trials

NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma

Pharma Times

APRIL 2, 2025

Advancing care for stage 3 or 4 Hodgkin lymphoma patients

Amivantamab plus lazertinib shows survival benefit in lung cancer

Pharma Times

MARCH 27, 2025

Janssen drug combination extends life expectancy during trial

Nouscom reveals promising results for lynch syndrome immunotherapy

Pharma Times

MARCH 26, 2025

NOUS-209 shows potential to intercept cancer in its early stages

Orca Bio’s T-cell therapy shows promise in haematological malignancies

Pharma Times

MARCH 19, 2025

The company is preparing to submit the results to the FDA this year

UKHSA announces new effort to tackle hepatitis C

Pharma Times

MARCH 18, 2025

The agency has launched a whole genome sequencing service to monitor the virus

Careology and Entia join forces to transform cancer care

Pharma Times

MARCH 17, 2025

Collaboration brings remote care to cancer patients

Minoryx doses first patient with leriglitazone in Rett syndrome study

Pharma Times

MARCH 12, 2025

Phase 2a TREE study assesses safety and efficacy of leriglitazone

New weight-loss pill shows promising results

Pharma Times

MARCH 11, 2025

Oxford Medical Products targets overweight individuals

NHS patients receive UK-donated plasma medicines for first time in 30 years

Pharma Times

MARCH 6, 2025

Octapharma supports NHS in building resilient supply chain

SECuRE trial pre-chemo participants experience PSA level drops

Pharma Times

MARCH 5, 2025

Cohort expansion phase commences with promising results

Rotherham NHS Foundation Trust enhances patient engagement

Pharma Times

MARCH 5, 2025

Innovative digital transformation leads to significant improvements

Blood cancer patients face treatment access disparity

Pharma Times

MARCH 3, 2025

New research highlights NHS approval gap compared to other cancers

Mitazalimab shows promising survival rates in cancer study

Pharma Times

FEBRUARY 26, 2025

Updated data from phase 2 study reveals survival benefit

FDA approves Deciphera’s Romvimza for rare tumour type

Pharma Times

FEBRUARY 20, 2025

Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations

UK study highlights importance of GP data in understanding atrial fibrillation

Pharma Times

FEBRUARY 19, 2025

The common heart condition affects approximately 1.

Cambridge scientists develop ‘super test’ for prostate cancer

Pharma Times

FEBRUARY 17, 2025

New test aims to revolutionise prostate cancer screening

Andembry treatment approved across Europe

Pharma Times

FEBRUARY 13, 2025

Significant progress for hereditary angioedema condition

Illuccix therapy gets approval in the UK

Pharma Times

FEBRUARY 13, 2025

Imaging agent to improve prostate cancer detection

Capgemini unveils AI breakthrough to boost bioeconomy

Pharma Times

FEBRUARY 10, 2025

New methodology may boost innovation in protein engineering

FDA grants Orphan Drug Designation to Ariceum cancer therapy

Pharma Times

FEBRUARY 6, 2025

Designation follows promising preclinical data and FDA clearance

Novartis secures MHRA authorisation for ribociclib

Pharma Times

FEBRUARY 5, 2025

Breast cancer therapy offers hope for patients at risk of recurrence

Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies

Pharma Times

FEBRUARY 4, 2025

Partnership aims to create recombinant nanobodies to treat immune disorders

Immunity

Immunity Immunization

Aplagon secures EUR 7 million for APAC phase 2a trials

Pharma Times

FEBRUARY 3, 2025

Funding led by new investors FSG and EIC Fund

CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients

Pharma Times

FEBRUARY 3, 2025

Positive opinion issued for marketing authorisation extension

FDA approves new Alzheimer’s treatment regimen

Pharma Times

JANUARY 28, 2025

Patients and care partners may find once every four weeks maintenance dosing easier

Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol

Pharma Times

JANUARY 23, 2025

Phase 3 trial shows promising pain relief for acute pain patients

Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment

Pharma Times

JANUARY 23, 2025

Orphan drug designation offers development incentives and potential market exclusivity

AstraZeneca receives positive recommendations for lung cancer treatments

Pharma Times

JANUARY 22, 2025

NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care

Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease

Pharma Times

JANUARY 22, 2025

Europes first biomarker trial seeks to prevent Crohns Disease onset

EC approves lazertinib in combination with amivantamab for NSCLC patients

Pharma Times

JANUARY 21, 2025

Combination therapy shows superior survival benefit over standard treatment

UK sees 70% increase in phase I advanced therapy clinical trials in 2024

Pharma Times

JANUARY 20, 2025

Cell and Gene Therapy Catapult reveals significant growth in UK trials

Datapharm expands into US market through partnership with phactMI

Pharma Times

JANUARY 20, 2025

Collaboration aims to enhance accessibility of medicines information

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

Pharma Times

JANUARY 16, 2025

New partnership to advance precision medicine in lung cancer diagnosis

Pharma Times

Lynozyfic receives EU approval for relapsed multiple myeloma treatment

Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine

Trending Sources

FDA approves Click’s digital therapeutic for episodic migraine

Lab-grown lung cancer cells show potential to revolutionise treatment

First treatment for common bladder cancer recommended by NICE

SkyCell and Microsoft partner to improve pharma supply chains

MHRA approves prostate cancer imaging agent trofolastat

SMC approves bimekizumab for hidradenitis suppurativa treatment

Endlyz Therapeutics emerges with pipeline for Parkinson’s disease

Elekta and Azra AI partner to advance cancer registry operations with AI

4basebio receives MHRA licence for synthetic DNA manufacture

NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma

Amivantamab plus lazertinib shows survival benefit in lung cancer

Nouscom reveals promising results for lynch syndrome immunotherapy

Orca Bio’s T-cell therapy shows promise in haematological malignancies

UKHSA announces new effort to tackle hepatitis C

Careology and Entia join forces to transform cancer care

Minoryx doses first patient with leriglitazone in Rett syndrome study

New weight-loss pill shows promising results

NHS patients receive UK-donated plasma medicines for first time in 30 years

SECuRE trial pre-chemo participants experience PSA level drops

Rotherham NHS Foundation Trust enhances patient engagement

Blood cancer patients face treatment access disparity

Mitazalimab shows promising survival rates in cancer study

FDA approves Deciphera’s Romvimza for rare tumour type

UK study highlights importance of GP data in understanding atrial fibrillation

Cambridge scientists develop ‘super test’ for prostate cancer

Andembry treatment approved across Europe

Illuccix therapy gets approval in the UK

Capgemini unveils AI breakthrough to boost bioeconomy

FDA grants Orphan Drug Designation to Ariceum cancer therapy

Novartis secures MHRA authorisation for ribociclib

Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies

Aplagon secures EUR 7 million for APAC phase 2a trials

CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients

FDA approves new Alzheimer’s treatment regimen

Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol

Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment

AstraZeneca receives positive recommendations for lung cancer treatments

Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease

EC approves lazertinib in combination with amivantamab for NSCLC patients

UK sees 70% increase in phase I advanced therapy clinical trials in 2024

Datapharm expands into US market through partnership with phactMI

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

Stay Connected